[go: up one dir, main page]

MX2013012233A - 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas. - Google Patents

4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.

Info

Publication number
MX2013012233A
MX2013012233A MX2013012233A MX2013012233A MX2013012233A MX 2013012233 A MX2013012233 A MX 2013012233A MX 2013012233 A MX2013012233 A MX 2013012233A MX 2013012233 A MX2013012233 A MX 2013012233A MX 2013012233 A MX2013012233 A MX 2013012233A
Authority
MX
Mexico
Prior art keywords
triazin
amines
aryl
phenyl
substituted
Prior art date
Application number
MX2013012233A
Other languages
English (en)
Inventor
Dirk Kosemund
Ulrich Lücking
Ulf Bömer
Rolf Bohlmann
Arne Scholz
Gerhard Siemeister
Mark Jean Gnoth
Gerd Rühter
Carsten Schultz-Fademrecht
Philip Lienau
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2013012233A publication Critical patent/MX2013012233A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

4-aril-N-fenil-1,3,5-triazin-2-aminas sustituidas y que presentan la fórmula general (I). Métodos para prepararlas. Su uso en el tratamiento y/o la profilaxis de diversos trastornos, particularmente de los trastornos hiperproliferativos, de las enfermedades infecciosas inducidas por virus y/o de las enfermedades cardiovasculares. Compuestos intermediarios útiles para preparar los compuestos de la fórmula general (I).
MX2013012233A 2011-04-19 2012-04-18 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas. MX2013012233A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11162996 2011-04-19
EP11177768 2011-08-17
EP11180012 2011-09-05
PCT/EP2012/057088 WO2012143399A1 (en) 2011-04-19 2012-04-18 Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines

Publications (1)

Publication Number Publication Date
MX2013012233A true MX2013012233A (es) 2014-01-23

Family

ID=45954688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012233A MX2013012233A (es) 2011-04-19 2012-04-18 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.

Country Status (13)

Country Link
US (1) US8916557B2 (es)
EP (1) EP2699554B1 (es)
JP (1) JP5912172B2 (es)
KR (1) KR20140019381A (es)
CN (1) CN103476759B (es)
AU (1) AU2012244745A1 (es)
CA (1) CA2833288A1 (es)
ES (1) ES2613103T3 (es)
IL (1) IL227975A (es)
MX (1) MX2013012233A (es)
RU (1) RU2013151118A (es)
WO (1) WO2012143399A1 (es)
ZA (1) ZA201306229B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026917B1 (ru) * 2010-03-22 2017-05-31 Лид Дискавери Сентр Гмбх Фармацевтически активные производные двузамещенного триазина
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2909183B1 (en) 2012-10-18 2016-08-24 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
JP2017531003A (ja) 2014-10-16 2017-10-19 バイエル ファーマ アクチエンゲゼルシャフト スルホン基を含有するフッ化ベンゾフラニル−ピリミジン誘導体
CA2999931A1 (en) 2015-09-29 2017-04-06 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
CN108368129B (zh) 2015-10-08 2021-08-17 拜耳医药股份有限公司 改性大环化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
EP3601253B1 (en) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CA3090843A1 (en) 2018-02-13 2019-08-22 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
ATE430742T1 (de) * 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
US7291616B2 (en) 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
DK2256108T3 (en) 2002-07-18 2016-04-11 Janssen Pharmaceutica Nv Substituted triazinkinaseinhibitorer
WO2004072063A1 (en) 2003-02-07 2004-08-26 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
CN101495481A (zh) * 2006-05-22 2009-07-29 先灵公司 作为CDK抑制剂的吡唑并[1,5-α]嘧啶
JP4305477B2 (ja) 2006-07-25 2009-07-29 トヨタ自動車株式会社 火花点火式内燃機関
WO2008012970A1 (en) 2006-07-27 2008-01-31 Nippon Mining & Metals Co., Ltd. Lithium-containing transition metal oxide target, process for producing the same and lithium ion thin-film secondary battery
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
CN101583365B (zh) * 2006-12-15 2012-09-26 阿布拉西斯生物科学公司 三嗪衍生物及其治疗应用
AU2007336933A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
MX2009006535A (es) * 2006-12-22 2009-06-26 Novartis Ag Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
CN101861313B (zh) 2007-03-12 2014-06-04 Ym生物科学澳大利亚私人有限公司 苯基氨基嘧啶化合物及其用途
ES2539518T3 (es) * 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
WO2009032861A1 (en) 2007-09-04 2009-03-12 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
NZ590320A (en) 2008-07-14 2012-12-21 Gilead Sciences Inc Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
EP2488503A1 (en) 2009-10-12 2012-08-22 Myrexis, Inc. Amino - pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon
EA026917B1 (ru) * 2010-03-22 2017-05-31 Лид Дискавери Сентр Гмбх Фармацевтически активные производные двузамещенного триазина

Also Published As

Publication number Publication date
ES2613103T3 (es) 2017-05-22
EP2699554A1 (en) 2014-02-26
KR20140019381A (ko) 2014-02-14
HK1192757A1 (zh) 2014-08-29
AU2012244745A1 (en) 2013-09-19
US20140045852A1 (en) 2014-02-13
ZA201306229B (en) 2014-11-26
EP2699554B1 (en) 2016-11-02
CA2833288A1 (en) 2012-10-26
WO2012143399A1 (en) 2012-10-26
JP5912172B2 (ja) 2016-04-27
CN103476759A (zh) 2013-12-25
US8916557B2 (en) 2014-12-23
RU2013151118A (ru) 2015-05-27
CN103476759B (zh) 2016-03-16
JP2014511889A (ja) 2014-05-19
IL227975A0 (en) 2013-09-30
IL227975A (en) 2015-10-29

Similar Documents

Publication Publication Date Title
TN2013000485A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
TN2015000185A1 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
CA2917096C (en) Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
IN2015DN01156A (es)
WO2014060375A3 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
PH12015500347A1 (en) 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
BR112014009866A2 (pt) formulações de anticorpos e métodos
TN2015000186A1 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
MX375872B (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas.
PH12016501968A1 (en) Novel macrocyclic compounds
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
NZ702458A (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
WO2014060493A3 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
TN2014000112A1 (en) Ep1 receptor ligands
HK1201067A1 (en) Sialic acid analogs
IN2015DN00085A (es)
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
EA019080B9 (ru) α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА
PH12015502703A1 (en) Pharmaceutical compositions
TH148747A (th) 4-อัลริล-n-ฟีนิล-1,3,5-ไตรอะซิน-2-เอมีนที่มีหมู่ซัลโฟซิมีน